ALX ONCOLOGY HOLDINGS INC Income Statement
ALXO|3 years of annual SEC 10-K data (FY2020-FY2022)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 3 fiscal years. All figures from audited SEC 10-K filings.
ALX ONCOLOGY HOLDINGS INC reported $0 in revenue and $123M in net loss for FY2022. Revenue increased 132.0% from FY2020 to FY2021.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 0.95 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2022 | FY2021 | FY2020 |
|---|---|---|---|
| Revenue | $0 | $4.8M | $2.1M |
| SG&A Expense | $29.0M | $3.3M | $2.6M |
| R&D Expense | $98.4M | $16.3M | $11.3M |
| Operating Income | -$127.4M | -$19.2M | -$13.7M |
| Interest Expense | $238.0K | - | - |
| Income Tax | $64.0K | $34.0K | $45.0K |
| Net Income | -$123.5M | -$19.2M | -$13.7M |
| EPS (Basic) | -$2.76 | - | - |
| EPS (Diluted) | -$2.76 | -$7.56 | -$6.33 |
| Shares Outstanding | 40.6M | 39.8M | 3.2M |
| Operating Margin | - | -400.0% | -662.0% |
| Profit Margin | - | -401.2% | -664.3% |